Stephen P. Carey, senior vice president and chief financial officer of ANI Pharmaceuticals Inc. (NASDAQ: ANIP), sold 2,850 shares of common stock on October 29, 2026, for a total value of $207,679. The shares sold at prices ranging from $72.18 to $73.29.
According to the report, the sale was executed under a Rule 10b5-1 trading plan that Carey adopted on March 6, 2026. Following the sale, Carey directly beneficially owns 166,143 shares.
The report also cites recent company results. ANI reported adjusted second-quarter 2026 earnings of $2.21 per share, above Wall Street's estimate of $2.03, and record revenue of $266 million, above forecasts of $262.14 million. The company cut its full-year guidance for Cortrophin Gel by $20 million to $25 million after underperformance in the first half, though it still expects 50% to 55% year-over-year growth for the product.
Guggenheim maintained a Buy rating and lowered its price target from $124 to $119. Canaccord Genuity lowered its target to $90 from $91. Oppenheimer initiated coverage with a Perform rating and an $85 price target.